Effect and safety of dual anti-human epidermal growth factor receptor 2 therapy compared to monotherapy in patients with human epidermal growth factor receptor 2-positive breast cancer: a systematic review

Peer Review reports

Original Submission
12 Mar 2014	Submitted	Original manuscript
12 Mar 2014	Author responded	Author comments - Jia He
Resubmission - Version 2
12 Mar 2014	Submitted	Manuscript version 2
Resubmission - Version 3
	Submitted	Manuscript version 3
8 May 2014	Reviewed	Reviewer Report - Thomas Ruhstaller
3 Jun 2014	Reviewed	Reviewer Report - Yu-Hao Zhou
11 Jun 2014	Reviewed	Reviewer Report - Stefan Diem
4 Jul 2014	Author responded	Author comments - Jia He
Resubmission - Version 4
4 Jul 2014	Submitted	Manuscript version 4
16 Aug 2014	Author responded	Author comments - Jia He
Resubmission - Version 5
16 Aug 2014	Submitted	Manuscript version 5
Resubmission - Version 6
	Submitted	Manuscript version 6
16 Aug 2014	Author responded	Author comments - Jia He
Resubmission - Version 7
16 Aug 2014	Submitted	Manuscript version 7
Publishing
21 Aug 2014	Editorially accepted
28 Aug 2014	Article published	10.1186/1471-2407-14-625

Back to article page